Sanara MedTech (Sanara MedTech) Accounts Receivable

: $8.48 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Sanara MedTech's accounts receivables for the quarter that ended in Dec. 2023 was $8.48 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Sanara MedTech's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 43.72.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Sanara MedTech's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-1.78.

Sanara MedTech Accounts Receivable Historical Data

The historical data trend for Sanara MedTech's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanara MedTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

1.29

2.22

2.86

6.81

8.48

Sanara MedTech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Receivable																6.81	6.47	7.14	7.44	8.48

Sanara MedTech Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Sanara MedTech Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Sanara MedTech's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	8.475	/	17.69	*	91
=	43.72

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Sanara MedTech's accounts receivable are only considered to be worth 75% of book value:

Sanara MedTech's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(5.147	+	0.75 * 8.475	+	0.5 * 4.718	-	29.283
-	0	-	-0.244)	/	8.53524
=	-1.78

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Sanara MedTech Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Sanara MedTech's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanara MedTech (Sanara MedTech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sanara MedTech Inc (NAS:SMTI) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1200 Summit Avenue, Suite 414, Fort Worth, TX, USA, 76102

Website

https://www.sanaramedtech.com

Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel.

Executives

Eric D Major	director	751 MILLER DRIVE SE, LEESBURG VA 20175
Zachary B. Fleming	officer: President - Surgical Div.	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Shawn M. Bowman	officer: President - Wound Care Div.	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Rebecca E Mcmahon	officer: President - R&D	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Sara N Ortwein	director	5959 LAS COLINAS BOULEVARD, IRVING TX 75039-2298
Robert Andrew Desutter	director	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Eric D Tanzberger	director	1929 ALLEN PARKWAY, HOUSTON TX 77219
Christopher A. Morrison	officer: President - Telehealth Svcs.	1200 SUMMIT AVENUE, SUITE 414, FORT WORTH TX 76102
Roszell Iii Mack	director	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Cgi Cellerate Rx, Llc	10 percent owner	C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Catalyst Rochal, Llc	10 percent owner	C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Bradley J. Gurasich	10 percent owner	C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
J Michael Carmena	director, officer: Principal Executive Officer	1200 SUMMIT AVE STE 414, FORT WORTH TX 76102
Michael D. Mcneil	officer: Chief Financial Officer	1200 SUMMIT AVE, STE 414, FORT WORTH TX 76102
Catalyst Group, Inc.	10 percent owner	1375 ENCLAVE PARKWAY, HOUSTON TX 77077